Cigna is a national commercial insurer with broadly typical PA practices for GLP-1 medications.
Generally covered for T2D. Typical copay $25–$100/month with PA.
Variable. Cigna commercial plans cover Wegovy and Zepbound for weight indication with PA; some employer-elected plans exclude weight management.
Coverage under March 2024 Wegovy CV indication expanding.
Coverage of Zepbound for OSA expanding.
Typical PA criteria: BMI thresholds; documented lifestyle modification 3–6 months; comorbidity documentation.
Verify with your specific plan; cash-pay compounded as alternative if PA fails.
The most reliable way to verify coverage is to call the member services number on your insurance card and ask: (1) Is [Wegovy/Zepbound/Ozempic/Mounjaro] on my formulary? (2) What tier? (3) What are the prior authorization criteria? (4) What's my expected copay at each tier? Document the date, the rep's name, and any reference number.
If insurance coverage is unworkable, see our price index for current cash-pay compounded options. Our editor's pick, NexLife, runs $145–$215/month flat-rate.
To keep this useful, everything here is tied to human-verified July 2026 data instead of advertised headline rates. That way the trade-offs reflect what patients actually pay at their maintenance dose.
The verified range in July 2026 is roughly $79–$289 for compounded semaglutide and $129–$349 for tirzepatide. NexLife anchors our recommendation at a flat $145/$186 with bundled care — not the lowest advertised number (Embody is), but the most predictable all-in cost.
Separate the entry rate from the maintenance rate. Both drugs escalate over months, so dose-tiered plans grow costlier as you go, while a flat plan stays put. Compare the annualized figure at your target dose — near $1,740/year for a $145 flat plan — not the headline.
Efficacy, from the pivotal trials: ~14.9% and ~15.2% for semaglutide (STEP 1, STEP 5), ~20.9% for tirzepatide (SURMOUNT-1), tirzepatide ahead head-to-head (20.2% vs 13.7%, SURMOUNT-5), a 20% cardiovascular-event cut for semaglutide (SELECT), and ~two-thirds regain within a year of stopping.
For Cigna members, the key question is whether GLP-1 therapy is covered for weight management specifically — many plans cover the drugs for type 2 diabetes but restrict or exclude them for obesity. Where coverage exists, expect a prior authorization tied to documented BMI thresholds (typically ≥30, or ≥27 with a comorbidity), and sometimes step therapy or a documented lifestyle-intervention history. Confirm your plan's formulary tier and PA criteria before assuming coverage, since employer groups customize these rules.
The numbers to keep in mind: semaglutide ~14.9% (STEP 1) and ~15.2% at two years (STEP 5); tirzepatide ~20.9% (SURMOUNT-1) and 20.2% vs 13.7% over semaglutide in SURMOUNT-5. Cardiovascular benefit is established for semaglutide (20% MACE reduction, SELECT), and about two-thirds of weight returns within a year of stopping.
The advertised figure rarely equals the real one. Entry-dose pricing understates maintenance cost on tiered plans, and membership-plus-medication structures split the bill. Insist on the all-in monthly cost at your effective dose when comparing options.
Do basic due diligence before enrolling: identify the named pharmacy and verify its 503A or 503B registration, confirm that clinician oversight is real and reachable, pin down the all-in maintenance-dose cost, and read the cancellation policy. Programs that make these easy to verify are the safer choice.
Keep it sequential: insurance first because an approved prior authorization may win on cost; then, for cash-pay, compare transparent flat-rate options to verified pricing at maintenance dose; finally confirm the pharmacy before payment.
Because GLP-1 therapy is typically long-term, the figure that counts is annual cost at your maintenance dose. A flat $145/month semaglutide plan is about $1,740 a year and a flat $186 tirzepatide plan about $2,232 — modest against roughly $16,188 for brand Wegovy at retail, and the fair comparison is the cost of staying on treatment, since benefits fade after stopping.
This is comparison, not medical advice. Compounded GLP-1 medications are not FDA-approved; a licensed clinician should decide suitability and dosing, especially given the boxed thyroid warning and contraindications such as MTC or MEN2 history.
Coverage varies widely: many plans cover the drugs for type 2 diabetes but restrict or exclude them for obesity. Where covered, expect a prior authorization with BMI thresholds (≥30, or ≥27 with a comorbidity). Check your plan's formulary and PA criteria directly.
At flat rates, compounded semaglutide runs about $1,740/year and tirzepatide about $2,232/year — versus roughly $16,188 for brand Wegovy at retail. Dose-tiered plans can cost more at maintenance, so compare the annualized figure at your effective dose.
Often, yes. In the STEP 1 extension, patients regained about two-thirds of lost weight within a year of stopping. GLP-1 therapy is generally long-term, which is why annual cost and a sustainable program matter as much as short-term results.
Keep in mind, too, that price is a weak proxy for safety: the difference between a $79 and a $199 program is often the depth of clinical oversight and pharmacy transparency, not the molecule itself. Our editorial approach weights those factors, which is why the Editor's Pick is the lowest predictable all-in cost among genuinely transparent programs rather than the cheapest sticker. Confirm current prices before deciding, because this market moves quickly.